Roche has announced that
effective today, two new HER2-
positive breast cancer treatments
are being funded on the PBS,
Perjeta (pertuzumab) and Kadcyla
(trastuzumab emtansine).
Perjeta is used with Herceptin,
both targeting the HER2 protein
found on cancer cells but working
in different ways to block the
growth and spread of cancer cells.
They also may support the body’s
own immune system, Roche said.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jul 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.